Careteq (ASX:CTQ) Debt-to-Asset : 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Careteq Debt-to-Asset?

Careteq ASX:CTQ +9.09% Debt-to-Asset is 0.00 as of Dec. 2025. The stock has 6 warning signs investors should review.

Careteq's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Careteq's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Careteq's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was A$4.44 Mil. Careteq's debt to asset for the quarter that ended in Dec. 2025 was 0.00.


Careteq  (ASX:CTQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Careteq Debt-to-Asset Related Terms


Careteq Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Careteq's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq Debt-to-Asset Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Asset
0.01 0.00 0.13 0.03 0.40

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only 0.10 0.03 0.03 0.40 0.00

ASX:CTQ vs VEEV, BTSG, HQY: Debt-to-Asset Comparison

For the Health Information Services subindustry, Careteq's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Careteq Debt-to-Asset vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Careteq's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Careteq's Debt-to-Asset falls into.



Careteq Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Careteq's Debt-to-Asset for the fiscal year that ended in Jun. 2025 is calculated as

Careteq's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Careteq (ASX:CTQ) has a Debt-to-Asset of 0.00 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Careteq and its competitors.
Is Careteq's Debt-to-Asset too high?
Careteq's current Debt-to-Asset is 0.00.
How does Careteq's Debt-to-Asset compare to VEEV and BTSG?
Careteq's Debt-to-Asset of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Healthcare Providers & Services company?
A good Debt-to-Asset depends on the Healthcare Providers & Services industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Careteq and its competitors. Careteq's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Debt-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current Debt-to-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.